Park Ha Biological Technology Co., Ltd. Ordinary Shares
BYAH
NASDAQ Global Market1.25
USD
+0.08
- -
CIK
0001986247
ISIN
KYG6925R1103
CUSIP
G6925R110
Return %
Stock
S&P500
1Y
-94.78
26.53
3Y
-94.78
76.60
5Y
-94.78
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Xiaoqiu Zhang
- Full Time Employees
- 31
- Sector
- Consumer Cyclical
- Industry
- Personal Products & Services
- Address
- 901 & 901-2 Wuxi People's Republic of China 214000
- IPO Date
- Oct 24, 2025
- CIK
- 0001986247
- Website
- parkha.cn
- Similar Companies
- Business
- Park Ha Biological Technology Co., Ltd. (Nasdaq: BYAH) develops and sells private-label skincare products under its proprietary Park Ha brand in China; operates in the Product Sales and Franchise Service segments; and provides complementary after-sales beauty services including light beauty experiences in directly operated and franchise stores. The company offers nearly 128 skincare products across 14 series covering basic skin physical protection, exfoliation, sebum film repair, surface microecological balance, and anti-aging categories; star products include the Little Blue Injection Serum, featuring multiple peptide active substances for hydration, moisturizing, brightening, and firming, as well as freeze-dried powders with fibronectin and cherry blossom extract for firmer, tender skin; additional offerings comprise Park Ha Amino Acid Cleansing Foam and other formulations developed through in-house research at its Jiangsu Park Ha Biological Technology Co., Ltd. subsidiary in collaboration with institutions like Jiangnan University, with production outsourced to licensed third-party manufacturers under strict ingredient and quality controls. Founded in 2016 and headquartered at 901 & 901-2, Building C, Phase 2, Wuxi International Life Science Innovation Campus, 196 Jinghui East Road, Xinwu District, Wuxi, Jiangsu Province, People's Republic of China, the company conducts operations through Chinese subsidiaries Jiangsu Park Ha Biological Technology (R&D and direct stores), Shanghai Park Ha Industrial Development (franchisee training), and Wuxi Xinzhan Enterprise Management Consulting (marketing and franchising); as of April 30, 2024, it maintains two directly operated stores and 43 franchisees, with 41 under the Park Ha name and two under Geni. In December 2024, Park Ha completed a $4.8 million initial public offering on Nasdaq Capital Market by selling 1,200,000 ordinary shares at $4.00 each, granting underwriters a 45-day option for 180,000 additional shares, with net proceeds allocated to expanding directly owned stores in China, acquiring product patents for proprietary development, and purchasing ingredient suppliers to lower long-term production costs; the company operates as a subsidiary of Xiaoqiu Holding Ltd.
Rosen Law Firm Encourages Park Ha Biological Technology Co. Ltd. Investors to Inquire About Securities Class Action Investigation – BYAH
Rosen Law Firm Encourages Park Ha Biological Technology Co. Ltd. Investors to Inquire About Securities Class Action Investigation – BYAH
Park Ha Biological Technology Co., Ltd. Announces Pricing of US$2.45 Million Best-Efforts Follow-on Public Offering